💊
Trisenox
arsenic trioxide
Acute promyelocytaire leukemie
✅ Geautoriseerd
✅
Geen actieve meldingen
Dit geneesmiddel heeft geen lopende tekorten, veiligheidsbrieven of terugroepacties.
Waarvoor het wordt gebruikt
Trisenox is indicated for induction of remission, and consolidation in adult patients with: Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 103/µl) in combination with all?trans?retinoic acid (ATRA) Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.
⚠️ Patiëntveiligheid
No
📚 Voorgaande meldingen (2)
Officiële EMA-pagina
https://www.ema.europa.eu/en/medicines/human/EPAR/trisenox